Company Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Kα inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
In addition, it has collaboration and license agreements with D. E.
Shaw Research, LLC to research certain biological targets through the use of D. E.
Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971.
The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.
Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 323 |
| CEO | Sanjiv Patel |
Contact Details
Address: 399 Binney Street, 2nd Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 617 370 8837 |
| Website | relaytx.com |
Stock Details
| Ticker Symbol | RLAY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001812364 |
| CUSIP Number | 75943R102 |
| ISIN Number | US75943R1023 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | Chief Executive Officer, President and Director |
| Alexis A. Borisy A.M. | Co-Founder and Independent Chairman |
| Dr. Mark Murcko Ph.D. | Co-Founder and Director |
| Thomas Catinazzo | Chief Financial Officer |
| Brian R. Adams J.D. | Chief Legal Officer and Secretary |
| Peter Rahmer | Chief Corporate Development Officer |
| Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research and Development |
| Dorothee Kern Ph.D. | Founder |
| Dr. David Elliot Shaw Ph.D. | Founder |
| Matthew P. Jacobson Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 144 | Filing |
| Oct 28, 2024 | 144 | Filing |
| Sep 27, 2024 | 144 | Filing |
| Sep 11, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 424B5 | Filing |
| Sep 9, 2024 | 424B5 | Filing |
| Sep 9, 2024 | 8-K | Current Report |